Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Avail Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,220,824

162 payments

Through program year 2025, Avail Clinical Research LLC is reported as receiving $1,220,824 in research payments, across 162 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $1,000 2
2022 Research $60,615 12
2021 Research $20,637 18
2020 Research $266,472 52
2019 Research $872,100 78

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $493,500 6 payments
  2. Pfizer Inc. $315,969 99 payments
  3. Novartis Pharmaceuticals Corporation $143,277 3 payments
  4. GlaxoSmithKline, LLC. $82,683 10 payments
  5. AbbVie, Inc. $81,467 28 payments
  6. Intercept Pharmaceuticals, Inc. $59,132 5 payments
  7. Ironwood Pharmaceuticals, Inc $36,181 7 payments
  8. Merck Sharp & Dohme Corporation $4,250 2 payments
  9. Celgene Corporation $3,364 1 payment
  10. RedHill Biopharma Inc. $1,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects $493,500 6 payments
  2. A Randomized, Double-Blind, Parallel-Group, Multicenter Study of Secukinumab to Compare 300 MG and 150 MG at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During An Initial 16 We $143,277 3 payments
  3. A Phase 1 Randomized Multicenter Doubleblind Sponsor Open Placebocontrolled Single and Multiple Doseescalation Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Pf06835375 in Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis $119,085 29 payments
  4. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $79,437 36 payments
  5. A Phase 2 Placebocontrolled Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Two 3Dose Regimens of A Clostridium Difficile Vaccine in Healthy Adults Aged 65 to 85 Years $68,404 17 payments
  6. 1010016 $59,132 5 payments
  7. An Observational Study to Evaluate the Immunogenicity of Mrna Eua Covi $50,465 7 payments
  8. M15-999 $37,257 11 payments
  9. C3718-301 $36,181 7 payments
  10. A Phase 2A Randomized Doubleblind Placebocontrolled Doseranging Parallel Group Study to Evaluate Safety Tolerability and Pharmacodynamics of Pf05221304 Administered Daily for 16Weeks to Adult Subjects With Nonalcoholic Fatty Liver Disease $35,678 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record